Notably, this switch from a Th1 tumor-suppressive phenotype, which aids cytotoxic CD8+ T cells in tumor rejection, to a Th2 tumor-promoting “regulatory” phenotype, which blocks CD8+ T-cell activity, is a characteristic outcome in the inflammatory, immune-suppressive tumor microenvironment (35). This evidence concerns the gene CD8A and neoplasm.